Report of the third Asian Prostate Cancer study meeting

Abstract

The Asian Prostate Cancer (A-CaP) study is an Asia-wide initiative that was launched in December 2015 in Tokyo, Japan, with the objective of surveying information about patients who have received a histopathological diagnosis of prostate cancer (PCa) and are undergoing treatment and clarifying distribution of staging, the actual status of treatment choices, and treatment outcomes. The study aims to clarify the clinical situation for PCa in Asia and use the outcomes for the purposes of international comparison. Following the first meeting in Tokyo in December 2015, the second A-CaP meeting was held in Seoul, Korea, in September 2016. This, the third A-CaP meeting, was held on October 14, 2017, in Chiang Mai, Thailand, with the participation of members and collaborators from 12 countries and regions. In the meeting, participating countries and regions presented the current status of data collection, and the A-CaP office presented a preliminary analysis of the registered cases received from each country and region. Participants discussed ongoing challenges relating to data input and collection, institutional, and legislative issues that may present barriers to data sharing, and the outlook for further patient registrations through to the end of the registration period in December 2018. In addition to A-CaP–specific discussions, a series of special lectures were also delivered on the situation for health insurance in the United States, the correlation between insurance coverage and PCa outcomes, and the outlook for robotic surgery in the Asia-Pacific region. Members also confirmed the principles of authorship in collaborative studies, with a view to publishing original articles based on A-CaP data in the future.

United in Fight against prOstate cancer (UFO) registry: first results from a large, multi‐centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia

“…We also found regional variations in the distribution of surgical procedures for radical prostatectomy; although this may reflect practice preferences in the background of the surgeon’s type of procedural qualification (whether robot‐assisted or laparoscopic qualification vs extensive experience in performing open radical prostatectomy), as well as availability of specialised facilities to perform the procedure at the individual study sites, rather than national or regional trends. This is consistent with regional reports that have noted a decrease in the use of radical prostatectomy in Asia between 2006 and 2013, and increasing use of robot‐assisted surgery in some countries, e.g., in Japan, where robot‐assisted surgery has been approved under the Japanese health insurance system .…”

“…These differences may reflect local practices and guidelines or drug/procedure availability and national reimbursement schemes. The heterogeneity between different countries in Asia is also highlighted by the Asian Prostate Cancer study, which is collecting information on patients with all stages of prostate cancer in Asia .…”

Patient-reported outcomes after surgery or radiotherapy for localised prostate cancer: a retrospective study

“…8,9 Currently, most Asian patients with localised prostate cancer choose active intervention as treatment; active surveillance is not commonly practised in the region. 10 The two most commonly performed treatments for prostate cancer in Asia are RT and RALP. Therefore, our study focused on assessing the outcomes of these two treatment modalities.…”

Prostate cancer trajectory-map: clinical decision support system for prognosis management of radical prostatectomy

“…In this study, we used the standard format of Asia prostate cancer (A-CaP) study. 10 The A-CaP study started in 2015 and has held annual symposium. The A-CaP study has two objectives.…”